

Supplemental Figure 1. Red blood cell (RBC) unit processing by whole-blood or red blood cell filtration

(A) Whole-blood-filtered units were collected into a top-top collection set with 66.6 mL of citrate-phosphate-dextrose anticoagulant (CPD). Whole blood was leukoreduced by filtration at room temperature and processed into an RBC unit and a plasma unit by centrifugation and decantation. Next, 105 mL of additive solution containing saline, adenine, glucose, and mannitol (SAGM) was added.

(B) RBC-filtered units were collected using top-bottom collection sets with 66.6 mL of CPD. Whole blood (WB) was rapidly cooled to 18–24°C after collection. RBCs, platelets and plasma were separated by centrifugation and decantation using a Compomat automat (Fresenius Kabi, Bothell, WA, USA); RBC were leukoreduced by filtration at room temperature and 105 mL of SAGM was added.

RT, room temperature.

Recipients

287 patients in the 10 French centers of the ABLE trial

7 did not consent to the IMIB study

280 included patients

2 without RBC transfusion

278 transfusion recipients

278 transfusion recipients analyzed

RBC units

1577 RBC units transfused



347 units not available for analysis

3 apheresis units excluded from statistical analysis

Units from PAR-2 excluded (n=1)

1226 units analyzed

Supplemental Figure 2. Flow chart of study patients and RBC units.



Supplemental Figure 3. Gating strategy for PEV and EEV quantification.

A. CD41⁺ and CD31⁺ correspond to total PEVs.

B. GPA⁺ CD47⁺ correspond to total EEVs and GPA⁺ CD47^{high} correspond to EEVs with high expression of CD47 protein.